COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Author(s)
Li X1, Wudong G2, Wang Y2
1National Health Commission, Beijing, China, 2China National Health Development Research Center, Beijing, China
OBJECTIVES : Liver cancer is the most common cancer with limited treatment options for patients at advanced stage. Lenvatinib was proved to be non-inferior compared to the only targeted cancer drug sorafenib for the treatment of unresectable hepatocellular carcinoma (HCC) in the Phase III REFLECT trial. This study was to develop a cost-effectiveness model of lenvatinib for the first-line treatment of unresectable hepatocellular carcinoma (HCC) in China based on data from REFELECT trail. METHODS : A partitioned survival model (PSM) was developed with the following health states: progression-free, progressed and dead. The time horizon of the model was life time with payer’s perspective in China. Efficacy and safety data were extracted from the REFLECT trial. Utility values were derived from the European Quality-of-Life 5-Dimension Questionnaire, conducted with patients enrolled in the REFLECT trial. Direct medical costs were obtained from 8 hospitals located in eastern, middle and western China. Deterministic and probabilistic sensitivity analyses were performed. RESULTS : The incremental cost-effectiveness ratio (ICER) for lenvatinib versus sorafenib was ¥ 633,212 per quality-adjusted life year (QALY) gained. CONCLUSIONS : Lenvatinib is not expected to be a cost-effective use in healthcare system in China, assuming a cost-effectiveness threshold of 3 times per capita GDP per QALY, which is 216,600 RMB.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PCN77
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Drugs, Oncology